siRNA-mediated gene silencing

US9487779B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9487779-B2
Application numberUS-201414297378-A
CountryUS
Kind codeB2
Filing dateJun 5, 2014
Priority dateAug 5, 2002
Publication dateNov 8, 2016
Grant dateNov 8, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules.

First claim

Opening claim text (preview).

What is claimed is: 1. A mammalian cell comprising a first strand of RNA of 15 to 30 nucleotides in length having a 5′ end and a 3′ end, wherein the first strand is complementary to at least 15 nucleotides of a mutant Ataxin-3 transcript encoded by siC7 (5′-CTGTCCTGATAGGTCCCGCTGC-3′ SEQ ID NO: 16), siG10 (5′-CTGATAGGTCCCCCTGCTGC-3′ SEQ ID NO:18), siC7/8 (5′-CTGTCCTGATAGGTCCGGCTGC-3′ SEQ ID NO:20), or siC10 (5′-CTGATAGGTCCCGCTGCTGC-3′ SEQ ID NO:22), and wherein the 5′ end of the first strand of RNA is operably linked to a G nucleotide to form a first segment of RNA, and a second strand of RNA of 15 to 30 nucleotides in length having a 5′ end and a 3′ end, wherein at least 12 nucleotides of the first and second strands are complementary to each other and form a small interfering RNA (siRNA) duplex under physiological conditions, and wherein the siRNA silences only one allele of the targeted gene in the cell. 2. The cell of claim 1 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure. 3. The cell of claim 2 , wherein the loop structure contains from 4 to 10 nucleotides. 4. An isolated RNA duplex comprising a first strand of RNA having a 5′ end and a 3′ end, and a second strand of RNA, wherein the first strand comprises 22 nucleotides complementary to mutant Ataxin-3 transcript encoded by siC7 (5′-CTGTCCTGATAGGTCCCGCTGC-3′ SEQ ID NO: 16), siG10 (5′-CTGATAGGTCCCCCTGCTGC-3′ SEQ ID NO:18), siC7/8 (5′-CTGTCCTGATAGGTCCGGCTGC-3′ SEQ ID NO:20), or siC10 (5′-CTGATAGGTCCCGCTGCTGC-3′ SEQ ID NO:22), wherein the 5′ end of the first strand of RNA is operably linked to a G nucleotide to form a first segment of RNA, and wherein the second strand is complementary to all the nucleotides of the first strand. 5. The RNA duplex of claim 4 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure. 6. The RNA duplex of claim 4 , wherein the loop structure contains from 4 to 10 nucleotides. 7. An expression cassette comprising a nucleic acid encoding at least one strand of the RNA duplex of claim 4 . 8. A vector comprising the expression cassette of claim 7 . 9. A vector comprising two expression cassettes, a first expression cassette comprising a nucleic acid encoding the first strand of the RNA duplex of claim 4 and a second expression cassette comprising a nucleic acid encoding the second strand of the RNA duplex of claim 4 . 10. A cell comprising the expression cassette of claim 7 . 11. An isolated RNA duplex comprising a first strand of RNA having a 5′ end and a 3′ end, and a second strand of RNA, wherein the first strand comprises 22 nucleotides complementary to mutant APP transcript encoded by siT8/C9 (5′-ATTCTGCATCCAGATTCACT-3′ SEQ ID NO: 83), siT9/C10 (5′-TTCTGCATCCAGATTCACTT-3′ SEQ ID NO:85), siT10/C11 (5′-TCTGCATCCAGATTCACTTC-3′ SEQ ID NO:86), siT11/C12 (5′-TGCATCCAGATTCACTTCA-3′ SEQ ID NO:88), or siT12/C13 (5′-TGCATCCAGATTCACTTCAG-3′ SEQ ID NO: 90), wherein the 5′ end of the first strand of RNA is operably linked to a G nucleotide to form a first segment of RNA, and wherein the second strand is complementary to all the nucleotides of the first strand. 12. The RNA duplex of claim 11 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure. 13. The RNA duplex of claim 11 , wherein the loop structure contains from 4 to 10 nucleotides. 14. An expression cassette comprising a nucleic acid encoding at least one strand of the RNA duplex of claim 11 . 15. A vector comprising the expression cassette of claim 14 . 16. A vector comprising two expression cassettes, a first expression cassette comprising a nucleic acid encoding the first strand of the RNA duplex of claim 14 and a second expression cassette comprising a nucleic acid encoding the second strand of the RNA duplex of claim 14 . 17. A cell comprising the expression cassette of claim 14 . 18. A mammalian cell comprising an isolated first strand of RNA of 15 to 30 nucleotides in length having a 5′ end and a 3′ end, wherein the first strand is complementary to at least 15 nucleotides of mutant APP transcript encoded by siT8/C9 (5′-ATTCTGCATCCAGATTCACT-3′ SEQ ID NO: 83), siT9/C10 (5′-TTCTGCATCCAGATTCACTT-3′ SEQ ID NO:85), siT10/C11 (5′-TCTGCATCCAGATTCACTTC-3′ SEQ ID NO:86), siT11/C12 (5′-TGCATCCAGATTCACTTCA-3′ SEQ ID NO:88), or siT12/C13 (5′-TGCATCCAGATTCACTTCAG-3′ SEQ ID NO: 90), and wherein the 5′ end of the first strand of RNA is operably linked to a G nucleotide to form a first segment of RNA, and an isolated second strand of RNA of 15 to 30 nucleotides in length having a 5′ end and a 3′ end, wherein at least 12 nucleotides of the first and second strands are complementary to each other and form a small interfering RNA (siRNA) duplex under physiological conditions, and wherein the siRNA silences only one allele of the targeted gene in the cell. 19. The cell of claim 18 , wherein the first strand and the second strand are operably linked by means of an RNA loop strand to form a hairpin structure comprising a duplex structure and a loop structure. 20. The cell of claim 19 , wherein the loop structure contains from 4 to 10 nucleotides.

Assignees

Inventors

Classifications

  • Beta-glucuronidase (3.2.1.31) · CPC title

  • Animals comprising random inserted nucleic acids (transgenic) · CPC title

  • for the expression of a heterologous nucleic acid · CPC title

  • spanning the whole gene, or a large part of it · CPC title

  • against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9487779B2 cover?
The present invention is directed to small interfering RNA molecules (siRNA) targeted against an allele of interest, and methods of using these siRNA molecules.
Who is the assignee on this patent?
Univ Iowa Res Found
What technology area does this patent fall under?
Primary CPC classification C12N15/113. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).